Table 2 Distribution of patients based on high exacerbations and blood eosinophil counts (2014 cohort)
From: Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
Population | CPRD database N = 15,364 | Optum database N = 139,465 |
|---|---|---|
Patients with ≥ 2 exacerbations in index year, n | 4,708 | 53,085 |
Patients with eosinophil count in baseline period, n | 3,089 (65.6%) | 13,414 |
< 150 cells/μL | 1,093 (35.4%) | 4,926 (36.7%) |
150–299 cells/μL | 1,024 (33.1%) | 4,834 (36.0%) |
300–399 cells/μL | 448 (14.5%) | 1,869 (13.9%) |
≥ 400 cells/μL | 524 (17.0%) | 1,785 (13.3%) |
Total patients with eosinophil count in baseline period, n | 9,345 | 34,391 |
≥ 2 exacerbations and eosinophil count ≥300 cells/μL, n (%) | 972 (10.4%) | 3,654 (10.6%) |
≥ 2 exacerbations and eosinophil count ≥400 cells/μL, n (%) | 524 (5.6%) | 1,785 (5.2%) |